Spring Bank Pharmaceuticals Announces Grant of European Patent for SMNH Analogs Including SB 9200

MILFORD, Mass., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform, announced today that the European Patent Office has issued a decision to grant European Patent No. 1968612 (EU Application Number 06848625.7). The newly granted patent includes claims covering the composition of matter for certain SMNH compounds, including SB 9200, Spring Bank’s most advanced SMNH compound, and use of these compounds to treat Hepatitis B infections. The grant of claims in this European patent further extends the issuance of patents covering the composition of matter and use of certain SMNH compounds beyond the United States, China, Japan and Korea, amongst other jurisdictions in which Spring Bank owns patents in this family.

“The grant of the Spring Bank patent in the European Union covering the composition of matter and use for certain SMNH compounds, including our lead development candidate SB 9200, to treat Hepatitis B virus (HBV) infections is an important step forward in our efforts to broaden our intellectual property estate on a global basis,” said Martin Driscoll, President & Chief Executive Officer of Spring Bank Pharmaceuticals. “We now have important composition of matter and use patent coverage for SB 9200 in the largest global markets for HBV. We intend to continue to seek to expand the global intellectual property estate for SB 9200 and the next generation compounds derived from our SMNH platform.”

About Spring Bank’s Intellectual Property

We have a global intellectual property portfolio consisting of over 20 issued patents worldwide and multiple patent applications directed to our lead product candidates, together with trade secrets and know-how. We own one U.S. patent and multiple foreign patents with claims covering the composition of matter of SB 9200 that expire in December 2026 and a second U.S. patent with claims covering the composition of matter of SB 9200 that expires in June 2030, in each case, without considering potential patent term extensions. Many other patent applications relating to the aforementioned patent families as well as other inventions corresponding to the SMNH technology platform are pending in the United States and other jurisdictions worldwide.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary SMNH chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins or enzymes implicated in various disease states. The Company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body’s immune response to viral infections. Spring Bank believes that SB 9200 can play an important role in antiviral therapy by modulating the body’s immune response through its mechanisms of action to fight viral infections such as HBV and RSV.

Contact: Maeve Conneighton Argot Partners (212) 600-1902 maeve@argotpartners.com

Source:Spring Bank Pharmaceuticals, Inc.